# Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus.

> **NCT06150651** · PHASE1 · COMPLETED · sponsor: **Chulalongkorn University** · enrollment: 3 (actual)

## Conditions studied

- SLE (Systemic Lupus)

## Interventions

- **OTHER:** PiggyBac Transposon-Mediated CD19 CAR-T Therapy

## Key facts

- **NCT ID:** NCT06150651
- **Lead sponsor:** Chulalongkorn University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-01
- **Primary completion:** 2026-03-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06150651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06150651, "Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus.". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06150651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*